RR-001

N/A

Report date: 2025/03/07 20:00:40

Base Information

Drug NameRR-001
Drug Alias NameRR-001
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionTNF-related apoptosis-inducing ligand receptors agonistsCell replacements
TargetsTNF-related apoptosis-inducing ligand receptors
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRigenerand SRL
China Registration ClassN/A

Develop Information

Active CompaniesEIR Biotherapies SRLRigenerand SRL
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A